myqorzo aficamten tablet 5mg per tablet 14 tablets per blister 2 blisters per box

Description

Indication & Scope

MYQORZO® (Aficamten) is indicated for the treatment of adult patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), NYHA Class II–III, to improve exercise capacity and clinical symptoms.

Mechanism: Aficamten is a reversible cardiac myosin inhibitor that reduces excessive myocardial contractility by inhibiting actin–myosin cross-bridge formation, thereby decreasing left ventricular outflow tract (LVOT) obstruction.
Drug Class: Cardiac myosin inhibitor.
Clinical Use: Used for adults with symptomatic obstructive HCM to improve functional capacity and disease-related symptoms.

Specification

Generic Name	Aficamten Tablets
Brand Name	MYQORZO®
Ingredient	Aficamten
Dosage Form	Tablet
Package	PVC medicinal rigid sheet and medicinal aluminium‑foil packaging; 14 tablets per blister, two blisters per box
Conditions Treated	Symptomatic obstructive hypertrophic cardiomyopathy (HCM)
Taboos	Hypersensitivity to Aficamten or any component of the product; patients with LVEF <55%
Place of origin	United States
Prescription type	Prescription Drug (Rx)
Storage Conditions	Store tightly closed, below 25°C
Manufacturer	Cytokinetics, Incorporated
Registration Authority	U.S. Food and Drug Administration (FDA)
Approval number	NDA 219083
Date of Revision	2025
Shelf Life	Refer to the approved package labeling.

How to use ?

Recommended Dose: The recommended starting dose of MYQORZO is 5 mg orally once daily. The dose may be increased in 5 mg increments every two weeks based on echocardiographic assessment of cardiac function. The maximum recommended dose is 20 mg once daily.

Time: Administer orally once daily. Swallow the tablet whole with water.

Instructions for use: Regular echocardiographic monitoring is required throughout treatment to evaluate left ventricular ejection fraction (LVEF) and left ventricular outflow tract gradient (LVOT-G). Treatment should not be initiated in patients with LVEF below 55%. If clinically significant reductions in LVEF occur during therapy, treatment interruption or dose adjustment should be considered according to the approved prescribing information.

Interaction: Strong CYP3A4 inhibitors may increase systemic exposure to Aficamten and require dose adjustment, while strong CYP3A4 inducers may reduce drug exposure and decrease therapeutic efficacy. Patients should inform their healthcare provider of all concomitant medications before starting treatment.

Side effects: Common adverse reactions include dizziness, fatigue, palpitations, nausea, headache, and peripheral edema. Important safety risks include reduced left ventricular ejection fraction (LVEF) and heart failure, making regular cardiac monitoring essential throughout treatment.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indicatiaon, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support